Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Equal-Weight on Freeport-McMoRan, Raises Price Target to $34

Morgan Stanley analyst Carlos De Alba maintains Freeport-McMoRan (NYSE:FCX) with a Equal-Weight and raises the price target from $32 to $34.

byBenzinga Newsdesk

December 9, 2021

1 minute read

Morgan Stanley analyst Carlos De Alba maintains Freeport-McMoRan (NYSE:FCX) with a Equal-Weight and raises the price target from $32 to $34.

Here’s Why Chamath Sold Some SPCE And Believes In CLOV, SPACs

By Chris Katje

Today, 11:17 AM

One of the most polarizing figures in the SPAC investing world has been Chamath Palihapitiya.

CLOV

News

SG Blocks Reports Lead Seed Round In Moliving, No Terms Disclosed

By Benzinga Newsdesk

Today, 11:17 AM

Investment Intended to Fuel Expansion for the World’s First Luxury Nomadic Hospitality Solution JACKSONVILLE, Fla.--(BUSINESS WIRE)-- SG Blocks, Inc. (NASDAQ:SGBX) (“SG Blocks” or the

SGBX

Roblox Misses Q3 Expectations, Shares Plunge

By Anusuya Lahiri

Today, 11:17 AM

Roblox Corp (NYSE:RBLX) reported third-quarter FY22 Bookings growth of 10% year-on-year to $701.7 million, beating the consensus of $686.3 million.…

RBLX

Piper Sandler Maintains Overweight on RAPT Therapeutics, Raises Price Target to $34

By Benzinga Newsdesk

Today, 11:17 AM

Piper Sandler analyst Edward Tenthoff maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and raises the price target from $30 to $34.

RAPT

Morgan Stanley Maintains Equal-Weight on Freeport-McMoRan, Raises Price Target to $34

Related Posts

Here’s Why Chamath Sold Some SPCE And Believes In CLOV, SPACs

SG Blocks Reports Lead Seed Round In Moliving, No Terms Disclosed

Roblox Misses Q3 Expectations, Shares Plunge

Piper Sandler Maintains Overweight on RAPT Therapeutics, Raises Price Target to $34